Medtronic’s Strategic Growth Potential with Spyral RDN Technology Justifies Buy Rating

In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Medtronic, with a price target of $106.00.

Josh Jennings has given his Buy rating due to a combination of factors that highlight Medtronic’s strategic positioning and growth potential. The Spyral RDN technology is emerging as a significant growth engine for Medtronic, supported by a substantial patient pool in the U.S. estimated at 18 million individuals. This technology benefits from a favorable reimbursement landscape and strong public support, which enhances its market viability.
Furthermore, the economic potential is underscored by the pricing of the catheter procedures, which are projected at approximately $16,000 each. Even minimal market penetration could translate into a multi-billion-dollar revenue opportunity for Medtronic, marking it as one of the company’s most significant market prospects in recent decades. This potential, coupled with insights from industry experts and cardiologists, reinforces confidence in Spyral RDN’s ability to drive Medtronic’s organic revenue growth, justifying the Buy rating.

According to TipRanks, Jennings is a 3-star analyst with an average return of 2.3% and a 47.39% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Medtronic, and Boston Scientific.

In another report released on September 25, Bank of America Securities also maintained a Buy rating on the stock with a $100.00 price target.